A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects.

Trial Profile

A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs SRT 2379 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Feb 2012 Actual patient number chnaged from 34 to 39 according to ClinicalTrials.gov.
    • 17 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Actual initiation date (Aug 2011) added and official title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top